Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
09.01. | G MEDICAL INNOVATIONS HOLDINGS LIMITED: Dividend component details | 1 | ASX | ||
08.01. | G MEDICAL INNOVATIONS HOLDINGS LIMITED: Issued Units Outstanding as at 31 December 2024 | 1 | ASX | ||
05.01. | G MEDICAL INNOVATIONS HOLDINGS LIMITED: Monthly Disclosure Information as at 31 December 2024 | - | ASX | ||
G MEDICAL INNOVATIONS Aktie jetzt für 0€ handeln | |||||
02.01. | G MEDICAL INNOVATIONS HOLDINGS LIMITED: Dividend Reinvestment Plan Prices | 1 | ASX | ||
31.12.24 | G MEDICAL INNOVATIONS HOLDINGS LIMITED: Final Dividend/Distribution for period ending 31 Dec 2024 | 1 | ASX | ||
19.12.24 | G MEDICAL INNOVATIONS HOLDINGS LIMITED: Dividend Timetable | 2 | ASX | ||
06.12.24 | G MEDICAL INNOVATIONS HOLDINGS LIMITED: Issued Units Outstanding as at 30 November 2024 | 2 | ASX | ||
04.12.24 | G MEDICAL INNOVATIONS HOLDINGS LIMITED: Monthly Disclosure Information as at 30 November 2024 | - | ASX | ||
06.11.24 | G MEDICAL INNOVATIONS HOLDINGS LIMITED: Monthly Disclosure Information as at 31 October 2024 | 1 | ASX | ||
05.11.24 | G MEDICAL INNOVATIONS HOLDINGS LIMITED: Issued Units Outstanding as at 31 October 2024 | - | ASX | ||
04.10.24 | G MEDICAL INNOVATIONS HOLDINGS LIMITED: Issued Units Outstanding as at 30 September 2024 | - | ASX | ||
04.10.24 | G MEDICAL INNOVATIONS HOLDINGS LIMITED: Monthly Disclosure Information as at 30 September 2024 | - | ASX | ||
30.09.24 | G MEDICAL INNOVATIONS HOLDINGS LIMITED: Annual Report FYE 30 June 2024 | - | ASX | ||
05.09.24 | G MEDICAL INNOVATIONS HOLDINGS LIMITED: Issued Units Outstanding as at 31 August 2024 | - | ASX | ||
05.09.24 | G MEDICAL INNOVATIONS HOLDINGS LIMITED: Monthly Disclosure Information as at 31 August 2024 | - | ASX | ||
07.08.24 | G MEDICAL INNOVATIONS HOLDINGS LIMITED: Issued Units Outstanding as at 31 July 2024 | - | ASX | ||
06.08.24 | G MEDICAL INNOVATIONS HOLDINGS LIMITED: Monthly Disclosure Information as at 31 July 2024 | - | ASX |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
TELADOC HEALTH | 9,700 | -0,30 % | Amazon Adds Teladoc Health to Health Benefits Program | ||
BICO GROUP | 2,806 | -2,77 % | BD And Biosero Partner To Integrate Robotics With Flow Cytometry | WASHINGTON (dpa-AFX) - BD. (BDX), a global medical technology company, and Biosero, a developer of laboratory automation solutions, Thursday announced that they have entered into a framework... ► Artikel lesen | |
HIMS & HERS HEALTH | 29,490 | -0,57 % | Hims & Hers Health COO Melissa Baird verkauft Aktien im Wert von 1,99 Millionen US-Dollar | ||
GERATHERM MEDICAL | 3,640 | 0,00 % | Geratherm Medical Aktie: Fortschritte führen zum Erfolg! | Die Geratherm Medical AG, ein Spezialist für medizinische Temperaturmesstechnik, verzeichnet einen vielversprechenden Jahresbeginn 2025. Der Aktienkurs des Unternehmens stieg am 17. Januar auf 3,68... ► Artikel lesen | |
DEXCOM | 84,13 | -0,05 % | Dexcom CEO says 2025 is 'shaping up to be a good year' with Stelo launch, GenAI integration | ||
NUGEN MEDICAL DEVICES | 0,046 | +1,77 % | Unglaubliche News! Der Super-CEO der alle Türen öffnen kann! | ||
PLUS THERAPEUTICS | 1,170 | +1,56 % | Plus Therapeutics Announces Renewal Of Master Services Agreement With Telix | CANBERA (dpa-AFX) - Plus Therapeutics (PSTV) announced the renewal of its Master Services Agreement with Telix IsoTherapeutics Group. The MSA secures supply of cGMP Re-186, the radioisotope... ► Artikel lesen | |
HEALWELL AI | 1,190 | -0,42 % | HEALWELL AI schließt die Eigenkapitaltranche im Wert von 25,5 Millionen $ seiner aufgestockten Bought-Deal-Finanzierung ab | - HEALWELL hat die Eigenkapitaltranche seiner zuvor angekündigten aufgestockten Bought-Deal-Finanzierung in Höhe von 55 Millionen $ abgeschlossen und damit einen Bruttoerlös
von 25,5... ► Artikel lesen | |
INVITAE | 0,110 | 0,00 % | Invitae Aktie: Drastischer Kursverfall trotz Umsatzwachstum | Der Aktienkurs des Biotechnologieunternehmens Invitae ist in den letzten Tagen stark eingebrochen. Am 8. September fiel der Kurs um 25% auf 0,0003 USD, was einen besorgniserregenden Trend fortsetzt.... ► Artikel lesen | |
ATOSSA THERAPEUTICS | 0,906 | 0,00 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025 | SEATTLE, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment... ► Artikel lesen | |
EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 | - Improved loss from operations by 31% -
- Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health... ► Artikel lesen | |
SONOMA PHARMACEUTICALS | 2,520 | 0,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices | BOULDER, CO / ACCESSWIRE / December 5, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous... ► Artikel lesen | |
EMEIS | 5,785 | +2,46 % | emeis: Half-Year Review (H2 2024) of the Liquidity Agreement Entered Into With Natixis Oddo BHF | Regulatory News:
Under the liquidity agreement entrusted by emeis (the "Company") (Paris:EMEIS) to Natixis Oddo BHF, the following resources were recorded in the dedicated liquidity account as... ► Artikel lesen | |
ASENSUS SURGICAL | 0,305 | 0,00 % | KARL STORZ akquiriert den US-amerikanischen Robotik-Spezialisten Asensus Surgical | Tuttlingen / Research Triangle Park, USA (ots) - Das familiengeführte und international agierende Medizintechnikunternehmen KARL STORZ gibt die Akquisition des innovativen Robotik-Spezialisten Asensus... ► Artikel lesen | |
CYTOSORBENTS | 0,960 | -2,93 % | CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue | Fourth quarter product revenue growth estimated at 22% to 25% year-over-year Fourth quarter gross margin estimated to improve to approximately 70% Management will host in-person investor... ► Artikel lesen |